January 2024 in “Circulation” This commentary explores the role of PCSK9 as a target for drug development, underscoring that individuals with PCSK9 loss-of-function mutations experience significantly lowered LDL cholesterol levels and reduced coronary events, suggesting that full inactivation of PCSK9 is effective and safe.
391 citations
,
September 2015 in “Journal of Clinical Lipidology” This document extends previous recommendations by the National Lipid Association for managing dyslipidemia, focusing on lifestyle therapies, special patient groups, and strategies to enhance adherence and patient outcomes.
This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
August 2015 in “MOJ proteomics & bioinformatics” This study suggests that epithelial-derived pop-up keratinocytes (ePUKs) may improve regenerative medicine applications due to their specific phenotype and increased expression of proteins involved in regulating cellular movement and wound healing.
January 2023 in “Biomaterials Science” This study suggests that incorporating matrisomal components into biomaterials could enhance skin wound healing in mammals that do not naturally regenerate tissues like the axolotl and Acomys.